Back To: Home : Featured Technology : Liquid Biopsy

CLICK HERE FOR WHAT'S NEW IN:
 

High-performance enzymes from Codexis
March 2017
SHARING OPTIONS:

REDWOOD CITY, Calif.—Protein engineering company Codexis Inc. will now offer high-performance enzymes for customers using next-generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) for in-vitro molecular diagnostic applications, the company reported recently. The first such proprietary enzyme will target improved library prep for NGS users, with expected availability in beta-test format by Q2 2017.
 
“Enzymes are critical to the sensitivity and reliability of NGS and PCR analyses,” Michael Aldridge, senior vice president of Corporate & Strategic Development at Codexis, commented in a statement. “Historically, NGS and PCR work-flows relied on only modestly engineered enzymes. However, as users push NGS and PCR into new, more demanding applications, such as liquid biopsy and personalized medicine samples, more capable enzymes are required.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.